January 2017

Cytokine Biomarkers Can Predict Response to CAR T-Cell Treatment in CLL

January 16, 2017

Evidence-Based Oncology

At the 58th American Society of Hematology Annual Meeting & Exposition, Jan Joseph Melenhorst, PhD, presented results of a study evaluating biomarkers of response to anti-CD19 CAR T-cell treatment in patients diagnosed with chronic lymphocytic leukemia (CLL).

Phase 3 LyMa Trial: Rituximab After ASCT Increases OS in Mantle Cell Lymphoma

January 16, 2017

Evidence-Based Oncology

Phase 3 results from the LyMa trial have shown that rituximab, after autologous stem cell transplant (ASCT), prolongs event-free survival, progression-free survival, and overall survival (OS) in previously untreated young patients with mantle cell lymphoma (MCL) following ASCT.

Early Results Show Palbociclib Helps Sustain Patient Response to Ibrutinib in MCL

January 16, 2017

Evidence-Based Oncology

Early phase 1 results show that including the cyclin-dependent kinase 4/6 inhibitor palbociclib in the treatment plan of patients with mantle cell lymphoma can help overcome resistance to ibrutinib.

RESONATE-2 Continues to Impress With Single-Agent Ibrutinib for CLL/SLL at 29 Months

January 18, 2017

Evidence-Based Oncology

Despite the complexities associated with treating older patients diagnosed with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL), patients in the RESONATE-2 trial continue to present a favorable response to single-agent ibrutinib at a follow-up of 29 months.

Ibrutinib Prevents Cytokine-Release Syndrome After CAR T-Cell Therapy for B-Cell Neoplasms

January 18, 2017

Evidence-Based Oncology

A study in a mouse model found that mice receiving chimeric antigen receptor (CAR)-T immunotherapy plus ibrutinib demonstrated longer overall survival and reduced cytokine production than the mice not treated with ibrutinib.

ASH Symposium on Quality Addresses Health IT Challenges for the Provider and the Patient

January 20, 2017

Evidence-Based Oncology

The Special Symposium on Quality looked at how health information technology (IT) can be utilized to improve healthcare quality, enhance patient—provider shared decision making, and facilitate efforts in quality research.

Incorporating Nurse Specialists Into Hematology Care: Improved QOL for Patient and Provider

January 20, 2017

Evidence-Based Oncology

During the ASH Practice Partnership lunch, Joseph Alvarnas, MD, from the City of Hope, and editor-in-chief of Evidence-Based Oncologyâ„¢ moderated a panel discussion on the impact of including nurse practitioners, physician assistants, and clinical nurse specialists into hematology care.

ASH "Choosing Wisely Champions" Share Their Practice-Changing Success

January 20, 2017

Evidence-Based Oncology

At the 2016 annual meeting, the American Society of Hematology introduced the “Choosing Wisely Champions” to recognize the efforts of practitioners who are working to eliminate costly and potentially harmful overuse of tests and procedures.

American Society of Hematology's Tenets for Hematologists to Choose Wisely

January 23, 2017

Evidence-Based Oncology

Initiated by the American Board of Internal Medicine, Choosing Wisely® is a campaign that has seen participation by a number of different national medical organizations to promote conversations between clinicians and patients to ensure adequate, evidence-based care.

Healthcare Costs and Utilization After First-Line Therapy for Medicare DLBCL Patients

January 23, 2017

Evidence-Based Oncology

Patients diagnosed with diffuse large B-cell lymphoma (DLBCL) who relapsed following first-line treatment had higher rates of healthcare utilization and greater costs than the patients who had not relapsed.

Model to Predict Disease Complexity and Costs Associated With AHCT in Acute Leukemia

January 23, 2017

Evidence-Based Oncology

Disease status, MUD/MRD donor, myeloablative conditioning regimen, GVHD prophylaxis other than tacrolimus/sirolimus, and Medicare and/or Medicaid as payer are significant predictors for cost of care in patient with acute leukemia who undergo allogenic hematopoietic cell transplant (AHCT).

Healthcare Utilization and Costs Associated With the Treatment of Relapsed/Refractory MM

January 25, 2017

Evidence-Based Oncology

A poster presented at the 58th Annual Meeting & Exposition of the American Society of Hematology compared the utilization patterns and associated costs for recently approved and older drugs in patients with relapsed/refractory multiple myeloma in the United States.

Innovative Approach to Precision Trial Design: NCI-MATCH and Beat AML

January 25, 2017

Evidence-Based Oncology

At the 58th annual meeting of the 58th American Society of Hematology, representatives from 2 national clinical trials, Beat AML and NCI-MATCH, detailed how they were incorporating genomic profiling to assign patients to different treatment arms.